Anifrolumab Real-world Treatment Outcomes in Systemic Lupus Erythematosus
The Polish multicentre observational (non-interventional) study aiming to collect data on the characteristic of patients with systemic lupus erythematosus and clinical outcomes of anifrolumab administered in the scope of routine clinical practice.
| Condition(s) | Lupus Erythematosus, Systemic |
|---|---|
| Status | Recruiting |
| Study type | Observational |
| Summary | The Polish multicentre observational (non-interventional) study aiming to collect data on the characteristic of patients with systemic lupus erythematosus and clinical outcomes of anifrolumab administered in the scope of routine clinical practice. |
| Who can participate | Inclusion Criteria: 1. Adult (aged ≥18 years old) patients with SLE who received anifrolumab treatment in the frames of NDP in Poland. 2. Patients willing to participate in the study and signed Informed Consent Form (ICF). Exclusion Criteria: 1. Those who participated in anifrolumab clinical trial in the past, and/or those who participated/plans to participate in clinical trial on/after the date of first anifrolumab infusion through NDP. 2. Cognitive incapacity, unwillingness or language barriers precluding adequate understanding or cooperation. |
| Ages | 18 Years |
| Sex | All |
| Lead sponsor | AstraZeneca |
| Locations | Bydgoszcz, Poland; Bytom, Poland; Gdansk, Poland; Katowice, Poland; Krakow, Poland; Lodz, Poland (+5 more sites) |
| Start date | 2025-02-28 |
| NCT ID | NCT06673043 |
| Official listing | https://clinicaltrials.gov/study/NCT06673043 |